Showing 473 results
-
Press release /Basel, December 7, 2017 -Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of…
-
Press release /Designation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) R/r DLBCL…
-
Press release /The patients that completed the Migraine Care pilot program reported over 50% reduction in migraine disability and a significant improvement in their patient activation measure after six months …
-
Press release /Phase II study met primary endpoint, demonstrating promising visual acuity gains in patients with neovascular (wet) age-related macular degeneration Data shows the potential for less…
-
Press release /Deal includes reSET®, cleared by FDA for treatment of patients with Substance Use Disorder, and reSET-O(TM), potential treatment pending FDA clearance for patients with Opioid Use Disorder treated…
-
Press release /Collaboration will use real-world patient data and cognitive computing with aim of improving outcomes in advanced breast cancer Brings Novartis innovation and breast cancer expertise together with…
-
Press release /Der globale Hauptsitz wird räumlich zusammen mit dem Alcon Regionalbüro für Europa, den Nahen Osten und Afrika in Genf eingerichtet Das börsennotierte Unternehmen Alcon wird in Fribourg…
-
Ad hoc release /Decision based on five-year data from COMPASS-XT long-term safety study Alcon advises ophthalmic surgeons to cease further implantation Basel, August 29, 2018 - Reflecting its uncompromising…
-
Press release /CHICAGO, April 25, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening…
-
Press release /New five-year commitment includes donation of treatments worth more than USD 40 million and is expected to reach an estimated 1.3 million patients Novartis Foundation's new leprosy contact…